Lsa(F) Gene: The New Antibiotic Resistance Threat Hiding in Farm and Food Bacteria
Antimicrobial resistance is a slow-moving crisis that rarely makes the news until something breaks. The famous names get the attention: MRSA, carbapenem-resistant Enterobacterales, the last-resort drugs we keep burning through. But resistance doesn’t appear from nowhere. It shows up one gene at a time, usually in the places nobody is watching, like the bacteria living in pigs, in dairy fermentations, in the ordinary background of animal agriculture.
A newly characterized gene fits that pattern. It’s called Lsa(F), and it belongs to a family of proteins that shield bacterial ribosomes from antibiotics. What makes it worth a closer look is the combination of what it resists, where it lives, and how easily it travels.
The ABC-F family: resistance through ribosome protection
To understand Lsa(F), start with the machinery. A group of resistance proteins known as the ABC-F family works through a mechanism called ribosome protection. Instead of destroying the drug or changing its target, these proteins burn ATP to physically pry the antibiotic off the ribosome. The ribosome keeps working and the antibiotic gets shoved aside.
Several members of this family are already familiar: Msr, Vga, Lsa, and more recent arrivals like OptrA and PoxtA. Beyond the mechanism, they share one telling trait. The genes that encode them almost always sit on mobile genetic elements, things like plasmids, phages, integrative and conjugative elements, and transposons. That mobility is what lets resistance hop between species.
Lsa(F) is the latest entry in the catalog. It turned up in Streptococcus parasuis, a pig-associated bacterium that’s increasingly seen as an opportunistic pathogen able to cross into humans.
What Lsa(F) actually resists
The defining feature of Lsa(F) is combined resistance to three antibiotic classes at once:
- Pleuromutilins: tiamulin and valnemulin, used heavily in livestock for pigs and poultry, plus newer derivatives such as retapamulin and lefamulin now approved for human medicine.
- Lincosamides: lincomycin and clindamycin.
- Streptogramin A: virginiamycin M1, for example.
This profile gets abbreviated as PLS_A. When researchers cloned the gene and moved it into two unrelated test bacteria, Streptococcus suis and Staphylococcus aureus, both picked up resistance. The minimum inhibitory concentrations climbed hard. Against tiamulin, the increase reached 128-fold. Against the human-use drugs retapamulin and lefamulin, it was 64-fold. That isn’t a marginal shift. It’s the gap between a drug that works and a drug that doesn’t.
Structurally, Lsa(F) looks the part. It carries the conserved signatures of the ABC-F family, the Walker A and B motifs, the ABC signature, and the H-loop switches, and it lacks the transmembrane domain seen in some related transporters. Its sequence is 41.9 to 58.7 percent identical to other known Lsa variants. Close enough to sit in the same lineage, distinct enough to count as its own gene.
Where it hides: mobile elements and a telling neighbor
The gene doesn’t sit still. In Streptococcus, Lsa(F) shows up mostly on mobile genetic elements embedded in the chromosome, integrative and conjugative elements, their defective variants, and related islands, frequently landing at a known hotspot called the fda locus. In Lactococcus, it’s mostly carried on plasmids or fixed at a specific chromosomal site.
One detail matters for how concerned we should be. Almost everywhere Lsa(F) sits, whether on a plasmid or on a chromosomal element, a specific insertion sequence named ISLll1 is parked directly downstream. Together with a small upstream hypothetical gene, this forms a conserved three-part unit: hyp, Lsa(F), ISLll1. ISLll1 belongs to a family of insertion sequences already known to help antibiotic resistance genes relocate. It doesn’t damage the Lsa(F) reading frame. It sits beside it, which suggests it may be assisting the gene’s movement. That’s the kind of genetic layout that turns a rare gene into a spreading one.
It can jump between species
The most direct evidence of risk came from conjugation experiments. Researchers paired Lsa(F)-carrying S. parasuis strains with a recipient S. suis strain, and the resistance gene transferred. In every successful case it landed at the fda locus of the recipient, which immediately showed reduced susceptibility to pleuromutilins, lincosamides, and streptogramin A. Transfer frequencies were low but real, on the order of 10⁻⁷ to 10⁻⁸ per donor cell.
Not every strain handed the gene off. Some carried it on defective elements missing the transfer machinery, so the gene stayed put. But the fact that transfer happened at all, between two different streptococcal species, is the real headline. Bacteria don’t respect the species lines we draw, and a gene that moves from a pig-associated organism into one that causes human disease is a gene worth tracking.
How common is it, really?
For now, the answer is reassuringly rare. In a collection of 26 clinical S. parasuis isolates, the gene appeared in ten. Public databases surface only a scattering of positive strains, mostly within Streptococcus and Lactococcus species, drawn from China, Vietnam, and Myanmar. The authors describe its distribution as potentially an early phase of spread. Not widespread yet, but present across several countries and several related bacterial species.
There’s also a near-twin. A gene called Lsa(F)-like, sharing 81.2 percent identity, is widespread in Lactococcus lactis. It keeps the functional motifs but differs in the resistance-determining loop, so its exact role remains unsettled. Whether it confers the same resistance is still an open question.
Why this belongs to a One Health story
The throughline here is the dual use of pleuromutilins. These drugs began in veterinary medicine, and tiamulin and valnemulin are still animal-only. But structural tweaks produced retapamulin and lefamulin, now approved for human infections including resistant Streptococcus pneumoniae and Staphylococcus aureus. The same drug class is now under selection pressure in both farms and hospitals.
That shared pressure is the core problem. Bacteria in livestock are constantly exposed to pleuromutilins, which keeps selecting for any gene that grants even partial resistance. Genes like Lsa(F) can then sit quietly until a transfer event moves them into a human pathogen, at which point a drug we were relying on for serious infections begins to fail. Lactic acid bacteria, generally regarded as harmless and used in food and probiotics, also carry Lsa(F), which opens up the prospect of foodborne routes of spread.
The takeaway
Here’s my read on it. Lsa(F) is a newly characterized resistance gene with a worrying skill set. It resists a clinically expanding drug class, it rides mobile genetic elements, it’s flanked by an insertion sequence that may help it move, and it has already been shown to jump between bacterial species. Its prevalence is low today, and that’s exactly why the window to watch it is now.
For clinicians, it’s a reminder that resistance to the newer pleuromutilins is no longer theoretical. For veterinarians and food producers, it’s a reason to treat pleuromutilin use as the shared resource it is. And for surveillance programs, it’s a concrete target: monitor Lsa(F), watch its mobile neighbors, and treat its spread as a One Health problem rather than a veterinary footnote.
Key takeaways
- Lsa(F) is a novel ABC-F family gene that confers combined resistance to pleuromutilins, lincosamides, and streptogramin A (PLS_A).
- It was first identified in Streptococcus parasuis, a pig-associated bacterium.
- The gene rides mobile genetic elements and is flanked by the insertion sequence ISLll1, which may aid its movement.
- It has been shown to transfer from S. parasuis to S. suis through conjugation.
- Its current prevalence is low but spread across multiple countries and bacterial species, which is why active surveillance matters.
